Hello, Thanks for signing up for MarketBeat Daily Ratings—we’re excited to have you on board. Every weekday, you’ll get a curated summary of new “Buy” and “Sell” ratings from Wall Street’s top-rated analysts, the latest stock news, and bonus investing content—all delivered straight to your inbox. You’re just two quick steps away from completing your sign-up: 1. Make sure our emails go to your inbox Gmail users:
Mobile: Tap the three dots (…) in the top right and select Move to Inbox or Move to Primary
Desktop: Click the folder icon at the top and select Move to Inbox or Primary Apple Mail users:
Tap our email address at the top (next to From: on mobile), then select Add to VIP Other providers:
Reply to this message and add newsletters@analystratings.net to your contacts 2. Confirm your subscription Click this link to confirm your subscription. This verifies your account and ensures you receive your newsletters without interruption instead of getting stuck in your spam filter. Confirm your subscription here. After you confirm, feel free to download our popular free report, "7 Stocks to Buy and Hold Forever" with this link. Thanks again for subscribing—we look forward to being part of your investing journey. 
Matthew Paulson
Founder and CEO, MarketBeat. P.S. If you didn’t mean to subscribe, no problem—you can unsubscribe here.
This Month's Featured News Why Boston Scientific's Big Dip Could Be a Bigger OpportunityBy Nathan Reiff. Published: 3/24/2026. 
Key Points - Boston Scientific shares are down over 25% year-to-date after investors may have been disappointed by the company's 2026 sales guidance.
- Still, there are many positives that could entice investors keen to buy the dip, including strong free cash flow growth and the prospect of access to new markets with the impending completion of the Penumbra acquisition.
- A potential major catalyst for growth is the Champion trial, which could significantly increase the addressable patient pool of Boston Scientific's Watchman line.
- Special Report: Elon Musk's $1 Quadrillion AI IPO
Medical device manufacturer Boston Scientific Corp. (NYSE: BSX) has had a rough start to the year: shares are down about 26% year-to-date (YTD) and nearly a third over the past year. But investors who look beyond the headline stock move may see stronger fundamentals—Boston Scientific reported adjusted earnings per share of $0.80 for the last quarter, $0.02 above consensus. Indeed, a closer look at Boston Scientific's earnings shows underlying strength: its electrophysiology (EP) segment—and Watchman products in particular—have grown rapidly and appear poised to continue. The company is also expected to release results from its Champion-AF trial by the end of March, which could materially expand the product's addressable patient pool. That combination may tempt investors to buy the dip in BSX, though it's important to understand why shares fell and what risks remain. Is the Boston Scientific Dip Justified? Shares of BSX dropped after its February earnings release, despite revenue rising about 16% year over year and adjusted EPS beating expectations. Free cash flow improved significantly as well, up roughly 38% year over year to about $3.7 billion. What drove the post-earnings selloff? One key factor may have been the company's 2026 organic revenue guidance, which called for year-over-year growth of 10% to 11%—a meaningful slowdown from 2025's roughly 20% full-year growth. Part of that moderation reflects the near-term impact of discontinuing certain Axios catheters and other product lines earlier in the year. Management expects this will shave about 150 basis points (1.5 percentage points) off early-2026 growth. Still, much of Boston Scientific's business remains intact and expanding. The company is guiding for another year of growing free cash flow—around $4.2 billion in 2026—along with continued operating margin expansion and other improvements. The Champion Trial Could Be a Catalyst for Reversal A potential catalyst for reversing the share decline is the Champion trial, which compares Boston Scientific's Watchman stroke-prevention implant with oral anticoagulants. Investors should watch these results closely, because a positive outcome could expand the addressable patient pool for Watchman as much as fourfold—to about 20 million patients. If the trial is positive, the impact could be meaningful and multi-year, potentially unlocking millions of new eligible patients worldwide and driving sustained sales growth. Another growth driver could be the planned acquisition of neurovascular device maker Penumbra (NYSE: PEN). Penumbra's products would give Boston Scientific an entry into the mechanical thrombectomy market, where it currently has no presence. The $14.5 billion deal is partly financed by a $6 billion term loan secured in late February. While that adds financial pressure, rising free cash flow and solid fundamentals in Boston Scientific's core businesses may help ease near-term concerns. Risks and Analyst Perspectives Are Worth Keeping in Mind A clear downside risk is a negative Champion result. That outcome would likely undermine the thesis of accelerating Watchman sales and could materially weaken the company's revenue outlook—potentially putting the 10%–11% 2026 sales guidance in doubt. On the other hand, Wall Street remains largely optimistic. Of 25 analyst ratings, 23 are Buys and two are Holds. Several firms—including Stifel Nicolaus, Jefferies and Truist Financial—reissued Buy ratings in March, though some have trimmed price targets while maintaining their Buy calls. Still, analysts see upside: the consensus price target of $106.27 is more than 50% above BSX's current trading level. | 
Post a Comment
Post a Comment